Integrating ePReBMs From Phoenix in Respiratory Diseases
Key facts
- Who runs it
- University of Alberta
- Where
- Canada1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Terminated
- People taking part
- 7 people enrolled
- Started
- 11 Oct 2023
- Ended
- 6 May 2024
- Type of study
- Interventional
- Treatments tested
- Health Gauge AI-Based Wearable Device - Model: Phoenix
- Record updated
- 29 October 2024
- Why it stopped
- Resource Issues
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 14 criteriaShow less
Who can take part
- Male or female volunteers, at least 18 years of age at the time of screening visit
- Fluent in English and able to follow the instructions to use the Health Gauge AI-based Wearable Device
- Willing and cognitively able to sign informed consent
- Interstitial lung disease, chronic obstructive pulmonary disease, pulmonary hypertension, or a healthy control
Who cannot take part
- Subjects with electronic implants of any kind (e.g. pacemaker)
- An active medical conditions for which they are on chronic treatment with drugs
- History of active (clinically significant) skin disorders
- History of allergic response to plastic materials
- Pregnancy
- Broken, damaged or irritated skin or rashes near the sensor application sites
- Subjects who are physically or cognitively unable to normally perform activities of daily living, assessed at the discretion of the investigator
- Shortness of breath (any sort)
- Chronic cough
- Fatigue or difficulty sleeping
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Participants with respiratory disease experience often a worsening of their condition, with increasing symptoms such as cough and shortness of breath. This worsening, often called exacerbation or flare up, impacts on the life of the participants, since they become limited in their daily activities.
Read full original descriptionShow less
Healthcare is still based today on limited times for clinical appointments to perform investigations and to meet with specialists/clinicians. Very often, these evaluations do not reflect the way the disease is limiting the patient's life.
Wearable devices offer the opportunity to collect data on physical activities and important clinical parameters (such as how the patient is active or just staying in bed during the day), on a daily basis.
The HG Phoenix AI- based Smart Watch produced by Health Gauge, an Albertan company based in Edmonton, has the potential to measure heart rate, heart rate variability, blood pressure, pulse wave velocity, respiratory rate, temperature, arterial saturation, sleep pattern (deep, light sleep, awake time), duration and time, daily physical activities (site count and distance) and calories burnt in a simple and non-invasive fashion. Ideally, these parameters could be monitored and recorded 24 hours per 7 days per week.
This study aims to demonstrate that this device can be used for a long time at home and it is comfortable to use for the participants, that it is not dangerous and, possibly, that it can help to identify exacerbations before the currently available investigations.
The group in the trial
- Device: Health Gauge AI-Based Wearable Device - Model: PhoenixTreatment being tested
Treatment: Health Gauge AI-Based Wearable Device - Model: Phoenix
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Integrating Electronic Patient Reported Biometric Measures (ePReBMs) From the Health Gauge Phoenix Smart Watch in Respiratory Diseases
- Record updated
- 29 October 2024